These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31391125)

  • 1. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF
    Gabler L; Lötsch D; Kirchhofer D; van Schoonhoven S; Schmidt HM; Mayr L; Pirker C; Neumayer K; Dinhof C; Kastler L; Azizi AA; Dorfer C; Czech T; Haberler C; Peyrl A; Kumar R; Slavc I; Spiegl-Kreinecker S; Gojo J; Berger W
    Acta Neuropathol Commun; 2019 Aug; 7(1):128. PubMed ID: 31391125
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
    Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
    Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
    Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
    Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.
    Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G
    Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
    Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
    Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
    Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
    Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
    Ahn JH; Lee YW; Ahn SK; Lee M
    Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
    Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
    Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
    Li Y; Cheng HS; Chng WJ; Tergaonkar V
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
    Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
    J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
    Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
    PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 20. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
    Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
    J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.